Name: | rituximab |
---|---|
PubChem Substance ID: | 17397150 |
Synonyms: |
Rituxan; Rituximab; D02994; Rituximab (genetical recombination); 174722-31-7; Rituximab (genetical recombination) (JAN); Rituxan (TN); Rituximab (USAN)
|
Name: | rituximab |
---|---|
Name (isomeric): | DB00073 |
Drug Type: | biotech |
Synonyms: |
AntiCD20; Ig gamma-1 chain C region
|
Brand: | Rituxan, MabThera |
Category: | Antineoplastic Agents |
CAS number: | 174722-31-7 |
Indication: | For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. |
---|---|
Pharmacology: | Rituximab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells. |
Mechanism of Action: | The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis. |
Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production |
Half Life: | 0.8 hours (mammalian reticulocytes, in vitro) |
Clearance: | 0.34 L/day [RA patients] |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|